Notably, transcriptomic responses to such STAT3/STAT5 inhibition were accompanied by specific changes in STAT5 target gene levels, similar to those seen in AML and natural killer/T cell lymphoma (NKCL) [35]. This evidence concerns the gene STAT5B and acute myeloid leukemia.